{"nctId":"NCT00627393","briefTitle":"Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)","startDateStruct":{"date":"2008-04"},"conditions":["Neutropenia","Infection"],"count":114,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Standard antimicrobial therapy","Biological: Granulocyte transfusions"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard antimicrobial therapy"]},{"label":"3","type":"OTHER","interventionNames":["Drug: G-CSF/dexamethasone","Device: Apheresis machine"]}],"interventions":[{"name":"Standard antimicrobial therapy","otherNames":[]},{"name":"Granulocyte transfusions","otherNames":[]},{"name":"G-CSF/dexamethasone","otherNames":["Neupogen"]},{"name":"Apheresis machine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Severe neutropenia (Absolute Neutrophil Count \\< 500/mm\\^3) due to marrow failure caused by underlying disease or therapy\n* Must have one of the following: fungemia; bacteremia; proven or presumptive invasive tissue bacterial infection; or proven, probable, or presumptive invasive fungal infection\n\nExclusion Criteria:\n\n* Unlikely to survive 5 days\n* Evidence that patient will not be neutropenic at least 5 days\n* Previously enrolled in this study","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response","description":"Microbial response was defined as follows:\n\n* A negative blood culture test at 42 days after randomization for subjects with fungemia (candidemia or fusariosis) or bacteremia.\n* Improvement of signs and symptoms of infectious disease (complete or partial response) at 42 days after randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"41.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Alloimmunization, Defined as the Appearance of Anti-human Leukocyte Antigen (HLA) or Antineutrophil Antibodies","description":null,"classes":[]},{"type":"SECONDARY","title":"Serious Granulocyte Transfusion Reactions, Including Febrile, Allergic, and Pulmonary Reactions (Transfusion Arm Only)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation","description":"Time to GVHD incidence between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67","spread":null},{"groupId":"OG001","value":"0.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Incidence of Adverse Effects","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Fever Resolution","description":"Fever resolution between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":null},{"groupId":"OG001","value":"0.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Negative Test for Fungal Antigenemia (e.g., Galactomannan Antigenemia Among Participants With Invasive Aspergillosis)","description":null,"classes":[]},{"type":"SECONDARY","title":"Time to Negative Blood Culture for Participants With Positive Blood Culture at Baseline","description":null,"classes":[]},{"type":"SECONDARY","title":"Long-term Survival","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Serious Adverse Events in Granulocyte Donors","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Donor Availability (Proportion of Scheduled Granulocyte Transfusion Days on Which Granulocytes Were Available)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Evaluation of Granulocyte Yield","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"174.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Discontinuation of Granulocyte Transfusions Due to Toxicity or Intolerance","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":58},"commonTop":["Fever","Sinus tachycardia","Rigors and Chills","Hypertension","Hypotension"]}}}